The potential use of antibacterial peptide antibody indices in the diagnosis of rheumatoid arthritis and ankylosing spondylitis

Journal of Clinical Rheumatology

Volumn 12, Issue 1, 2006, Pages 11-16

  Rashid, Taha ^a   Ebringer, Alan ^a,b   Wilson, Clyde ^a   Bansal, Sukvinder ^a   Paimela, Leena ^c   Binder, Allan ^d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c Orton Hospital   (Finland)

^d LISTER HOSPITAL   (United Kingdom)

Author keywords

Ankylosing spondylitis; Diagnostic indices; Proteus and Klebsiella antibodies; Rheumatoid arthritis

Indexed keywords

BACTERIUM ANTIBODY; HEMOLYSIN; IMMUNOGLOBULIN G ANTIBODY; NITROGENASE; PULLULANASE; SYNTHETIC PEPTIDE; UREASE; IMMUNOGLOBULIN CLASS; PEPTIDE;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ANTIBODY DETECTION; ARTHRITIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KLEBSIELLA; MALE; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEUS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SERUM; BLOOD; CASE CONTROL STUDY; ENZYMOLOGY; IMMUNOLOGY; MICROBIOLOGY; MIDDLE AGED; SYNTHESIS;

ADULT; AGED; ANTIBODIES, BACTERIAL; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN ISOTYPES; KLEBSIELLA; MALE; MIDDLE AGED; PEPTIDES; PROTEUS; SPONDYLITIS, ANKYLOSING;

EID: 33745928741     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rhu.0000200374.14619.f2     Document Type: Article

References (42)

1. Maini RN, Feldmann M. Rheumatoid arthritis. In: Isenberg DA, Maddison PJ, Woo P, et al., eds. Oxford Textbook of Rheumatology. Oxford: Oxford University Press; 2004:677-732.
2. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987;30:1205-1213.
3. Watanabe Y, Tokunaga K, Matsuki K, et al. Putative amino acid sequence of HLA-DRβ chain contributing to rheumatoid arthritis susceptibility. J Exp Med. 1989;169:2263-2268.
4. Wallin J, Hillert J, Olerup O, et al. Association of rheumatoid arthritis with a dominant DR1/Dw4/Dw14 sequence motif, but not with T cell receptor beta chain gene alleles or haplotypes. Arthritis Rheum. 1991;34:1416-1424.
5. Ebringer A, Cunningham P, Ahmadi K, et al. Sequence similarity between HLA-DR1 and DR4 subtypes associated with rheumatoid arthritis and Proteus/Serratia membrane haemolysins. Ann Rheum Dis. 1992;51:1245-1246.
6. Tiwana H, Wilson C, Alvarez A, et al. Cross-reactivity between the rheumatoid arthritis-associated motif EQKRAA and structurally related sequences found in Proteus mirabilis. Infect Immun. 1999;67:2769-2775.
7. Wilson C, Ebringer A, Ahmadi K, et al. Shared amino acid sequences between major histocompatibility complex class II glycoproteins, type XI collagen and Proteus mirabilis in rheumatoid arthritis. Ann Rheum Dis. 1995;54:216-220.
8. Wilson C, Rashid T, Tiwana H, et al. Cytotoxicity responses to peptide antigens in rheumatoid arthritis and ankylosing spondylitis. J Rheumatol. 2003;30:972-978.
9. Deighton CM, Gray SW, Bint AJ, et al. Specificity of the Proteus antibody response in rheumatoid arthritis. Ann Rheum Dis. 1992;51:1206-1207.
10. Tiwana H, Wilson C, Cunningham P, et al. Antibodies to four Gram-negative bacteria in rheumatoid arthritis which share sequences with the rheumatoid arthritis susceptibility motif. Br J Rheumatol. 1996;35:592-594.
11. Goldbach-Mansky R, Senior B, Susan S, et al. IgM and IgA antibodies to Proteus mirabilis are associated with early RF positive RA. Arthritis Rheum. 2000;43(suppl):S190.
12. Ebringer A, Rashid T, Wilson C. Rheumatoid arthritis: proposal for the use of anti-microbial therapy in early cases. Scand J Rheumatol. 2003;32:2-11.
13. Ebringer A, Wilson C, Ahmadi K, et al. Rheumatoid arthritis as a reactive arthritis to Proteus infection: prospects for therapy. In: Machtey I, ed. 'Sixth International Seminar on the Treatment of Rheumatic Diseases'. Prog Rheumatol. 1993;5:77-83.
14. Wilson C, Thakore D, Isenberg D, et al. Correlation between anti-Proteus antibodies and isolation rates of P. mirabilis in rheumatoid arthritis. Rheumatol Int. 1997;16:187-189.
15. Brewerton DA, Hart FD, Nicholls A, et al. Ankylosing spondylitis and HL-A 27. Lancet. 1973;i:904-907.
16. Schlosstein L, Terasaki PI, Bluestone E, et al. High association of an HLA antigen, W27, with ankylosing spondylitis. N Engl J Med. 1973;288:704-706.
17. Schwimmbeck PL, Yu DTY, Oldstone MBA. Autoantibodies to HLA-B27 in the sera of HLA-B27 patients with ankylosing spondylitis and Reiter's syndrome: molecular mimicry with Klebsiella pneumoniae as potential mechanism of autoimmune disease. J Exp Med. 1987;166:173-181.
18. Husby G, Tsuchiya N, Schwimmbeck PL, et al. Cross-reactive epitope with Klebsiella pneumoniae nitrogenase in articular tissue of HLA-B27+ patients with ankylosing spondylitis. Arthritis Rheum. 1989;32:437-445.
19. Fielder M, Pirt SJ, Tarpey I, et al. Molecular mimicry and ankylosing spondylitis: possible role of a novel sequence in pullulanase of Klebsiella pneumoniae. FEBS Lett. 1995;369:243-248.
20. Tani Y, Tiwana H, Hukuda S, et al. Antibodies to Klebsiella, Proteus and HLA-B27 peptides in Japanese patients with ankylosing spondylitis and rheumatoid arthritis. J Rheumatol. 1997;24:109-114.
21. Ebringer A, Rashid T, Wilson C, et al. Ankylosing spondylitis, HLA-B27 and Klebsiella - an overview: proposal for early diagnosis and treatment. Curr Rheumatol Rev. In press.
22. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324.
23. Nienhuis RL, Mandema E. A new serum factor in patients with rheumatoid arthritis; the antiperinuclear factor (APF). Ann Rheum Dis. 1964;23:302-305.
24. Paimela L, Gripenberg M, Kurki P, et al. Antikeratin antibodies: diagnostic and prognostic markers for early rheumatoid arthritis. Ann Rheum Dis. 1992;51:743-746.
25. Paimela L, Palosuo T, Aho K, et al. Association of autoantibodies to filaggrin with an active disease in early rheumatoid arthritis. Ann Rheum Dis. 2001;60:32-35.
26. Bas S, Genevay S, Meyer O, et al. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford). 2003;42:677-680.
27. Jansen AL, van der Horst-Bruinsma I, van Schaardenburg D, et al. Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol. 2002;29:2074-2076.
28. Steiner G, Smolen J. Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res. 2002;4(suppl 2):S1-S5.
29. Mau W, Zeidler H, Mau R, et al. Clinical features and prognosis with possible ankylosing spondylitis. Results of a 10-year follow-up. J Rheumatol. 1988;15:1109-1114.
30. Rudwaleit M, van der Heijde D, Khan MA, et al. How to diagnose axial spondyloarthritis early. Ann Rheum Dis. 2004;63:535-543.
31. Oostveen J, Prevo R, den Boer J, et al. Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography. A prospective longitudinal study. J Rheumatol. 1999;26:1953-1958.
32. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361-368.
33. Merrifield RB. Solid-phase peptide synthesis. Adv Enzymol Relat Areas Mol Biol. 1969;32:221-296.
34. Rashid T, Leirisalo-Repo M, Tani Y, et al. Antibacterial and antipeptide antibodies in Japanese and Finnish patients with rheumatoid arthritis. Clin Rheumatol. 2004;23:134-141.
35. Hughes LE, Bonell S, Natt RS, et al. Antibody responses to Acinetobacter spp. and Pseudomonas aeruginosa in multiple sclerosis: prospects for diagnosis using the myelin-Acinetobacter-neurofilament antibody index. Clin Diag Lab Immunol. 2001;8:1181-1188.
36. Van Boekel MA, Vossenaar ER, van den Hoogen FHJ, et al. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res. 2002;4:87-93.
37. Sheldon J. Laboratory testing in autoimmune rheumatic diseases. Best Pract Res Clin Rheumatol. 2004;18:249-269.
38. Nijenhuis S, Zendman AJW, Vossenaar ER, et al. Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker. Clinica Chimica Acta. 2004;350:17-34.
39. Correa PA, Tobon GJ, Citera G, et al. Anti-cyclic citrulllinated peptide antibodies in rheumatoid arthritis: relation with clinical features, cytokines and HLA-DRB1. Biomedica. 2004;24:140-152.
40. Vander Cruyssen B, Hoffman IEA, Zmierczak H, et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis. 2005;64:1145-1149.
41. Takeuchi F, Kosuge E, Matsuta K, et al. Antibody to a specific HLA-DRβ1 sequence in Japanese patients with rheumatoid arthritis. Arthritis Rheum. 1990;33:1867-1868.
42. Dybwad A, Forre O, Sioud M. Increased serum and synovial antibodies to immunoselected peptides in patients with rheumatoid arthritis. Ann Rheum Dis. 1996;55:437-441.